Zacks Investment Research downgraded shares of Pure Bioscience, Inc. (PURE) from OUTPERFORM to NEUTRAL on December 13, 2012, with a target price of $1.75.
PURE develops and markets SDC-based antimicrobial products that provide non-toxic solutions to numerous global health challenges. SDC is a novel, patented platform technology with superior efficacy and low toxicity and can be used in diverse markets including personal care, preservatives, industrials, agriculture and pharmaceuticals. Although its lead product PURE Hard Surface is increasingly gaining recognition, sales may take longer to gain traction since PURE is still in its early stage of commercialization of its SDC technology.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on Pure Bioscience, Inc. (PURE),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment